share_log

8-K: Current report

8-K: Current report

8-K:重大事件
美股SEC公告 ·  05/22 16:18

Moomoo AI 已提取核心信息

Heart Test Laboratories, Inc., a company listed on the Nasdaq Capital Market, has announced that its delisting action by Nasdaq has been temporarily stayed. The stay is pending a final decision by a Nasdaq Hearing Panel following the company's appeal, which will be heard on June 27, 2024. The company had received a notice of delisting due to non-compliance with Nasdaq's Minimum Bid Price Requirement and Low Priced Stocks Rule, as its common stock had closed at $0.10 or less for ten consecutive trading days. Heart Test Laboratories had previously been granted an extension until July 29, 2024, to regain compliance with the Minimum Bid Price Requirement. In response to the delisting notice, the company implemented a 1-for-100 reverse stock split on...Show More
Heart Test Laboratories, Inc., a company listed on the Nasdaq Capital Market, has announced that its delisting action by Nasdaq has been temporarily stayed. The stay is pending a final decision by a Nasdaq Hearing Panel following the company's appeal, which will be heard on June 27, 2024. The company had received a notice of delisting due to non-compliance with Nasdaq's Minimum Bid Price Requirement and Low Priced Stocks Rule, as its common stock had closed at $0.10 or less for ten consecutive trading days. Heart Test Laboratories had previously been granted an extension until July 29, 2024, to regain compliance with the Minimum Bid Price Requirement. In response to the delisting notice, the company implemented a 1-for-100 reverse stock split on May 17, 2024. The company believes it has regained compliance with Nasdaq's listing requirements, but there is no guarantee that the appeal will be successful or that it will remain listed on Nasdaq. The company's common stock and public warrants will continue to trade on Nasdaq under the symbols 'HSCS' and 'HSCSW' respectively, pending the outcome of the hearing.
在纳斯达克资本市场上市的公司Heart Test Laboratories, Inc. 宣布,纳斯达克的退市行动已暂时中止。该公司的上诉将于2024年6月27日审理后,纳斯达克听证会小组做出最终决定,该上诉将暂停审理。该公司因不遵守纳斯达克的最低出价要求和低价股票规则而收到退市通知,因为其普通股连续十个交易日收于0.10美元或以下。心脏测试实验室此前已获准延期至2024年7月29日,以恢复对最低出价要求的遵守。作为对退市通知的回应,该公司于2024年5月17日实施了每100股的反向股票拆分。该公司认为已恢复遵守纳斯达克的上市要求,但无法保证上诉会成功或将继续在纳斯达克上市。在听证会得出结果之前,该公司的普通股和公开认股权证将继续在纳斯达克交易,代码分别为 “HSCS” 和 “HSCSW”。
在纳斯达克资本市场上市的公司Heart Test Laboratories, Inc. 宣布,纳斯达克的退市行动已暂时中止。该公司的上诉将于2024年6月27日审理后,纳斯达克听证会小组做出最终决定,该上诉将暂停审理。该公司因不遵守纳斯达克的最低出价要求和低价股票规则而收到退市通知,因为其普通股连续十个交易日收于0.10美元或以下。心脏测试实验室此前已获准延期至2024年7月29日,以恢复对最低出价要求的遵守。作为对退市通知的回应,该公司于2024年5月17日实施了每100股的反向股票拆分。该公司认为已恢复遵守纳斯达克的上市要求,但无法保证上诉会成功或将继续在纳斯达克上市。在听证会得出结果之前,该公司的普通股和公开认股权证将继续在纳斯达克交易,代码分别为 “HSCS” 和 “HSCSW”。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息